Ingenuity collaborates with Sage to enhance predictive disease networks

Ingenuity® Systems, a leading provider of information solutions for life science researchers, today announced a new collaboration with Sage Bionetworks, a non-profit leader in predictive disease network research.  Under the collaboration, Sage will leverage IPA®, Ingenuity's industry-leading analysis software, and the Ingenuity® Knowledge Base of structured biomedical Findings, to inform and enhance Sage's predictive disease networks. Additionally, Sage's web portal will provide links to the Ingenuity Knowledge Base and to IPA, to help visitors access timely, context-rich biomedical information and better understand it in a biological context.  Sage's content, algorithms, and predictive disease networks will also be made available within Ingenuity products like IPA®.

The Ingenuity-Sage collaboration will support therapeutic area researchers who are working to understand the complex developments in the diagnosis, treatment, and etiology of diseases.  Researchers will be able to use the content and algorithms from Sage within IPA to analyze molecular data, generate testable hypotheses, and build and visualize predictive disease models. These models will enable researchers to more rapidly identify and prioritize therapeutic targets for drug development and assess toxicity of potential drug candidates.

"We're very excited about our collaboration with Ingenuity Systems," stated Stephen Friend MD, PhD, President, Sage Bionetworks. "Leveraging their high-quality, expert-reviewed Ingenuity Knowledge Base Findings and their powerful pathway analytics in our research will enhance and add functionality to our predictive disease networks and algorithms."

"This represents a rare and precious opportunity to fundamentally advance the field of predictive disease networks," said Doug Bassett, Chief Science and Technology Officer at Ingenuity, "We're thrilled to be working with Sage in this context, and excited at the value this can bring to Sage and Ingenuity customers and partners.  We are committed to providing researchers with the very best predictive disease content and analytics within Ingenuity's products."

Source:

Ingenuity Systems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Is fruit juice good or bad for diabetes? New research reveals a genetic twist